Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Journal
Future oncology (London, England)
Journal Volume
19
Journal Issue
38
Date Issued
2023-12
Author(s)
Abou-Alfa, Ghassan K
Lau, George
Kudo, Masatoshi
Chan, Stephen L
Kelley, Robin Kate
Furuse, Junji
Sukeepaisarnjaroen, Wattana
Kang, Yoon Koo
Dao, Tu Van
De Toni, Enrico N
Rimassa, Lorenza
Breder, Valeriy
Vasilyev, Alexander
Heurgué, Alexandra
Tam, Vincent C
Mody, Kabir
Thungappa, Satheesh Chiradoni
Ostapenko, Yurii
Yau, Thomas
Azevedo, Sergio
Varela, María
Qin, Shukui
Galle, Peter R
Ali, Sajid
Gupta, Charu
Makowsky, Mallory
Kurland, John F
Negro, Alejandra
Sangro, Bruno
Abstract
This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer.
Subjects
Sorafenib; clinical trial; durvalumab; hepatocellular carcinoma; immunotherapy; lay summary; liver cancer; plain language summary; tremelimumab
Type
review